Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
BBP-418 FORTIFY (Phase 3) is a BridgeBio Pharma, Inc. program in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Its next catalyst is a Readout in Q4 2028.
Indication under review: Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Sponsor: BridgeBio Pharma, Inc. (BBIO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
When is BBP-418 FORTIFY (Phase 3)'s next FDA decision or readout?
The next tracked catalyst for BBP-418 FORTIFY (Phase 3) is a Readout in Q4 2028.
What happened at BBP-418 FORTIFY (Phase 3)'s most recent FDA decision?
No FDA decision for BBP-418 FORTIFY (Phase 3) is in our archive yet.
What is BBP-418 FORTIFY (Phase 3) used for?
In our records BBP-418 FORTIFY (Phase 3) is under review or in development for Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Who makes BBP-418 FORTIFY (Phase 3)?
BridgeBio Pharma, Inc. (BBIO).
Where does this data come from?
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.
Facts and dates only; not investment advice. Verify against primary FDA, SEC
and company filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.